Matches in SemOpenAlex for { <https://semopenalex.org/work/W2811355251> ?p ?o ?g. }
- W2811355251 endingPage "12" @default.
- W2811355251 startingPage "1" @default.
- W2811355251 abstract "Background . Neuroendocrine tumors (NETs) are characterized by having behavior and prognosis that depend upon tumor histology, primary site, staging, and proliferative index. The symptoms associated with carcinoid syndrome and vasoactive intestinal peptide tumors are treated with octreotide acetate. The PROMID trial assesses the effect of octreotide LAR on the tumor growth in patients with well-differentiated metastatic midgut NETs. The CLARINET trial evaluates the effects of lanreotide in patients with nonfunctional, well-, or moderately differentiated metastatic enteropancreatic NETs. Everolimus has been approved for the treatment of advanced pancreatic NETs (pNETs) based on positive PFS effects, obtained in the treated group. Sunitinib is approved for the treatment of patients with progressive gastrointestinal stromal tumor or intolerance to imatinib, because a randomized study demonstrated that it improves PFS and overall survival in patients with advanced well-differentiated pNETs. In a phase II trial, pasireotide shows efficacy and tolerability in the treatment of patients with advanced NETs, whose symptoms of carcinoid syndrome were resistant to octreotide LAR. An open-label, phase II trial assesses the clinical activity of long-acting repeatable pasireotide in treatment-naive patients with metastatic grade 1 or 2 NETs. Even if the growth of the neoplasm was significantly inhibited, it is still unclear whether its antiproliferative action is greater than that of octreotide and lanreotide. Because new therapeutic options are needed to counter the natural behavior of neuroendocrine tumors, it would also be useful to have a biochemical marker that can be addressed better in the management of these patients. Chromogranin A is currently the most useful biomarker to establish diagnosis and has some utility in predicting disease recurrence, outcome, and efficacy of therapy." @default.
- W2811355251 created "2018-07-10" @default.
- W2811355251 creator A5011245991 @default.
- W2811355251 creator A5022776448 @default.
- W2811355251 creator A5022810670 @default.
- W2811355251 creator A5026938369 @default.
- W2811355251 creator A5040165180 @default.
- W2811355251 creator A5061577134 @default.
- W2811355251 creator A5063939488 @default.
- W2811355251 creator A5065670109 @default.
- W2811355251 creator A5080662145 @default.
- W2811355251 date "2018-07-02" @default.
- W2811355251 modified "2023-10-14" @default.
- W2811355251 title "Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors" @default.
- W2811355251 cites W1526666898 @default.
- W2811355251 cites W1552233144 @default.
- W2811355251 cites W1569722645 @default.
- W2811355251 cites W1604592092 @default.
- W2811355251 cites W1679079033 @default.
- W2811355251 cites W1840972930 @default.
- W2811355251 cites W1942590761 @default.
- W2811355251 cites W1965167639 @default.
- W2811355251 cites W1977978236 @default.
- W2811355251 cites W1980393471 @default.
- W2811355251 cites W198232297 @default.
- W2811355251 cites W1992077567 @default.
- W2811355251 cites W1993526737 @default.
- W2811355251 cites W1995161288 @default.
- W2811355251 cites W1997563646 @default.
- W2811355251 cites W1998496809 @default.
- W2811355251 cites W1999405546 @default.
- W2811355251 cites W2000980666 @default.
- W2811355251 cites W2002962269 @default.
- W2811355251 cites W2003049002 @default.
- W2811355251 cites W2008774709 @default.
- W2811355251 cites W2011205419 @default.
- W2811355251 cites W2014390834 @default.
- W2811355251 cites W2015025080 @default.
- W2811355251 cites W2018550540 @default.
- W2811355251 cites W2020077746 @default.
- W2811355251 cites W2022001512 @default.
- W2811355251 cites W2022274068 @default.
- W2811355251 cites W2023059943 @default.
- W2811355251 cites W2023710246 @default.
- W2811355251 cites W2024641334 @default.
- W2811355251 cites W2026668428 @default.
- W2811355251 cites W2028523875 @default.
- W2811355251 cites W2029147573 @default.
- W2811355251 cites W2030663955 @default.
- W2811355251 cites W2031084325 @default.
- W2811355251 cites W2032237900 @default.
- W2811355251 cites W2034724751 @default.
- W2811355251 cites W2046995444 @default.
- W2811355251 cites W2048539018 @default.
- W2811355251 cites W2052540197 @default.
- W2811355251 cites W2058355382 @default.
- W2811355251 cites W2061071330 @default.
- W2811355251 cites W2065462700 @default.
- W2811355251 cites W2069392112 @default.
- W2811355251 cites W2070739652 @default.
- W2811355251 cites W2074161793 @default.
- W2811355251 cites W2076736672 @default.
- W2811355251 cites W2098009765 @default.
- W2811355251 cites W2100283328 @default.
- W2811355251 cites W2103264165 @default.
- W2811355251 cites W2106805342 @default.
- W2811355251 cites W2107028723 @default.
- W2811355251 cites W2110016520 @default.
- W2811355251 cites W2110254924 @default.
- W2811355251 cites W2110922803 @default.
- W2811355251 cites W2112064092 @default.
- W2811355251 cites W2115686439 @default.
- W2811355251 cites W2117017066 @default.
- W2811355251 cites W2120542624 @default.
- W2811355251 cites W2122730074 @default.
- W2811355251 cites W2125369986 @default.
- W2811355251 cites W2127981125 @default.
- W2811355251 cites W2130495579 @default.
- W2811355251 cites W2133780035 @default.
- W2811355251 cites W2134761192 @default.
- W2811355251 cites W2143360113 @default.
- W2811355251 cites W2143766305 @default.
- W2811355251 cites W2146946075 @default.
- W2811355251 cites W2148933046 @default.
- W2811355251 cites W2149214723 @default.
- W2811355251 cites W2150004274 @default.
- W2811355251 cites W2151068875 @default.
- W2811355251 cites W2152666438 @default.
- W2811355251 cites W2158247064 @default.
- W2811355251 cites W2163537725 @default.
- W2811355251 cites W2170333388 @default.
- W2811355251 cites W2279678576 @default.
- W2811355251 cites W2316555918 @default.
- W2811355251 cites W2319457872 @default.
- W2811355251 cites W2322817866 @default.
- W2811355251 cites W2395689465 @default.
- W2811355251 cites W2406211032 @default.
- W2811355251 cites W2411036900 @default.